|1.||Friden, P: 3 articles (12/2002 - 05/2001)|
|2.||Aho, Heikki: 2 articles (04/2005 - 02/2004)|
|3.||Laine, Jukka: 2 articles (04/2005 - 02/2004)|
|4.||Zagariya, Alexander: 2 articles (04/2005 - 02/2004)|
|5.||Vidyasagar, Dharmapuri: 2 articles (04/2005 - 02/2004)|
|6.||Tsang, Siu Wai: 2 articles (04/2003 - 03/2003)|
|7.||Leung, Po Sing: 2 articles (04/2003 - 03/2003)|
|8.||Che, Chun Tao: 2 articles (04/2003 - 03/2003)|
|9.||Wong, Tung Po: 2 articles (04/2003 - 03/2003)|
|10.||Ip, Siu Po: 2 articles (04/2003 - 03/2003)|
|1.||Hypertension (High Blood Pressure)
11/01/1979 - "The mean decline in diastolic blood pressure to saralasin in the subnormal adrenal responsive patients (-15 +/- 3 mm Hg) was significantly greater than in the normal adrenal responsive group (-3 +/- 2 mm Hg) (P < 0.02).It is concluded that patients with HREH are not a homogeneous population; approximately one-third have AII-dependent hypertension. "
02/01/1986 - "Taking into consideration international studies our results confirm that the Saralasin test, taking into account strongly standardized methodical prerequisites, is suited to objectify a participation of the RAAS in the hypertension pathogenesis, without, however, thus making an absolutely reliable evidence concerning the etiology of hypertension. "
05/01/1980 - "Studies were performed to determine whether the hypertension in this disorder could be corrected by saralasin infusion. "
11/01/1979 - "The AII competitive inhibitor, saralasin (0.3-30 mug/kg per min) was then infused to study the occurrence of angiotensinogenic hypertension in both HREH subgroups. "
12/01/1977 - "The results cast doubts on the clinical usefulness of saralasin in the investigation of patients with hypertension, when studied in the conditions of the present study."
02/01/2002 - "There was a significant reduction in the change from baseline to Day 22 in bleeding on probing in the 0.01% P-113 treatment group of the intent to treat population (p=0.049). "
05/01/2001 - "Similar trends were noted for changes in the % of sites with bleeding on probing in the 0.01% P-113 group. "
01/01/1990 - "MC did not affect the blood pressure recovery; however, saralasin reduced it to the post-hemorrhage levels. "
06/01/1986 - "However, injection of converting enzyme inhibitor (SQ 20881) or saralasin in order to block endogenous ANG II did not attenuate either basal or hemorrhage-stimulated drinking in the marine fish."
03/01/1985 - "Intravenous saralasin did not blunt the response to hemorrhage. "
03/28/2003 - "These data indicate that administration of saralasin but not ramiprilat could be protective against acute pancreatitis and that activation of pancreatic RAS in acute pancreatitis may play a role in pancreatic tissue injury."
04/01/2003 - "These data suggest that prophylactic administration of saralasin can ameliorate the oxidative stress and tissue injury in cerulein-induced pancreatitis. "
04/01/2003 - "In the current study we hypothesized that inhibition of this renin-angiotensin system by saralasin, a nonspecific antagonist for angiotensin II receptor, could attenuate the severity of cerulein-induced pancreatitis. "
04/01/2003 - "Saralasin, a nonspecific angiotensin II receptor antagonist, attenuates oxidative stress and tissue injury in cerulein-induced acute pancreatitis."
03/28/2003 - "Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis."
05/01/2001 - "There was a significant reduction in plaque (p=0.046) and a reduction in gingivitis (p=0.086) for subjects using 0.01% P-113 mouthrinse. "
05/01/2002 - "Animal studies and human clinical trials showed that P-113 has potential in preventing the development of gingivitis, with no adverse side effects. "
02/01/2002 - "During this time, the safety, anti-gingivitis, and anti-plaque effects of P-113 were evaluated. "
05/01/2001 - "During this time, the safety, anti-plaque, and anti-gingivitis effects of P-113 were evaluated. "
05/01/2001 - "P-113, a 12 amino acid histatin-based peptide, was evaluated in a mouthrinse formulation for safety, prevention of the development of experimental gingivitis, and for its effects on periodontal flora. "
|2.||Angiotensin Receptors (Angiotensin II Receptor)
|1.||Surgical Instruments (Clip)